Lugano, Switzerland, 21 June 2021 - The first edition of the ESMO Gynaecological Cancers Congress will be held as a virtual meeting on 25-26 June and will focus on ovarian cancer. (1)
Ovarian cancer is the most lethal gynaecological cancer and symptoms are difficult to recognise. As there is an absence of screening programmes, there is an important need to improve diagnosis, treatment and survival, as well as optimising prevention and early detection.
The Congress programme (2) will offer the latest insights and explore future developments in key areas:
- DNA damage repair and PARP inhibitors resistance, Keynote lecture by Amit Oza, Friday, 25 June, 12:45-13:20 CEST
- New treatment options for newly diagnosed and recurrent ovarian cancer
- Future applications of immunotherapy in clinical practice
Abstract sessions will also be dedicated to the recapitulation and critical review of the scientific breakthroughs presented during the year.
Media registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Only through the official accreditation process with the media registration form, accredited media representatives will be able to access pre-recorded presentations, live discussions, virtual exhibition, industry satellite symposia and Congress webcasts. (3)
The need of predicting testing - Read the article out now on ESMO Perspectives
Ahead of the event and, considering the urgency of predictive testing to improve prevention, diagnosis and treatment of ovarian cancer, Dr. Domenica Lorusso, ESMO Gynaecological Cancer Faculty Group, Fondazione Policlinico Gemelli IRCCS and Catholic University of Sacred Heart in Rome has given her expert view on the topic, sharing her reflections on ESMO's corporate magazine, ESMO Perspectives.
Below a preview of the article, that can be read in its full version here. (4)
DESPITE SUCCESS OF TARGETED THERAPIES, PERSONALISED MEDICINE IS NOT YET A REALITY IN OVARIAN CANCER
Ovarian cancer represents a significant unmet need in gynaecological cancers as the absence of well-defined screening programmes and inconsistent initial symptoms lead to late diagnosis in the majority of patients. Considered largely incurable, ovarian cancer typically relapses within 3 years in 80% of women, with subsequent recurrences arising sooner each time as resistance to chemotherapy develops. Despite significant therapeutic achievements with molecular targeted agents in the last five years, Dr. Domenica Lorusso, argues that saving more women in the future will require better tools to select patients for personalised treatment and identify those in whom the disease could be prevented altogether.
###
For further information
ESMO Press Office
media@esmo.org
Notes to Editors
Please make sure to use the official name of the meeting in your reports: ESMO Gynaecological Cancers Congress 2021
Official Congress Hashtag: #ESMOGynae2021
References
1) https://www.esmo.org/meetings/esmo-gynaecological-cancers-virtual-congress-2021
2) ttps://cslide.ctimeetingtech.com/gynae2021_v/attendee/confcal/session/calendar
3) https://esmo.formstack.com/forms/media_registration_form_gynae_2021
4) https://perspectives.esmo.org/latest-edition/featured-content/despite-success-of-targeted-therapies-personalised-medicine-is-not-yet-a-reality-in-ovarian-cancer
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. http://www.esmo.org